References

1.
Rayner SG, Scholl Z, Mandrycky CJ, Chen J, LaValley KN, Leary PJ, et al. Endothelial‐derived von Willebrand factor accelerates fibrin clotting within engineered microvessels. Journal of Thrombosis and Haemostasis 2022;20:1627–37. doi:10.1111/jth.15714.
2.
Smith NL, Rice KM, Bovill EG, Cushman M, Bis JC, McKnight B, et al. Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis. Blood 2011;117:6007–11. doi:10.1182/blood-2010-10-315473.
3.
Goodeve A. Diagnosing von Willebrand disease: genetic analysis. Hematology 2016;2016:678–82. doi:10.1182/asheducation-2016.1.678.
4.
Manderstedt E, Lind-Halldén C, Lethagen S, Halldén C. Common and Rare Variants in Genes Associated with von Willebrand Factor Level Variation: No Accumulation of Rare Variants in Swedish von Willebrand Disease Patients. TH Open 2020;04:e322–31. doi:10.1055/s-0040-1718885.
5.
Willebrand EA von. Hereditär pseudohemofili. Finska Läkaresällskapets Handlingar 1926:87–112.
6.
Sadler JE, Budde U, Eikenboom JCJ, Favaloro EJ, Hill FGH, Holmberg L, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. Journal of Thrombosis and Haemostasis 2006;4:2103–14. doi:10.1111/j.1538-7836.2006.02146.x.
7.
James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Advances 2021;5:280–300. doi:10.1182/bloodadvances.2020003265.
8.
Batlle J, Pérez-Rodríguez A, Corrales I, Borràs N, Costa Pinto J, López-Fernández MF, et al. Update on Molecular Testing in von Willebrand Disease. Seminars in Thrombosis and Hemostasis 2019;45:708–19. doi:10.1055/s-0039-1679922.
9.
Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J. Platelet‐dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 2015;13:1345–50. doi:10.1111/jth.12964.
10.
Abou-Ismail MY, James PD, Flood VH, Connell NT. Beyond the guidelines: how we approach challenging scenarios in the diagnosis and management of von Willebrand disease. Journal of Thrombosis and Haemostasis 2023;21:204–14. doi:10.1016/j.jtha.2022.11.042.
11.
Salem RO, Van Cott EM. A New Automated Screening Assay for the Diagnosis of von Willebrand Disease. American Journal of Clinical Pathology 2007;127:730–5. doi:10.1309/cepnd3lfhq87xu4d.
12.
Favaloro EJ, Mohammed S. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease. Thrombosis Research 2016;141:202–11. doi:10.1016/j.thromres.2015.12.010.
13.
Schneppenheim R, Patzke J. Laboratory diagnosis of von Willebrand disease. Hämostaseologie 2010;30:203–6. doi:10.1055/s-0037-1619057.
14.
Patzke J, Budde U, Huber A, Méndez A, Muth H, Obser T, et al. Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin. Blood Coagulation &Amp; Fibrinolysis 2014;25:860–70. doi:10.1097/mbc.0000000000000169.
15.
Othman M. Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder. Seminars in Thrombosis and Hemostasis 2011;37:464–9. doi:10.1055/s-0031-1281030.
16.
Castaman G, Tosetto A, Cappelletti A, Goodeve A, Federici AB, Batlle J, et al. Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. Thrombosis Research 2010;126:227–31. doi:10.1016/j.thromres.2010.06.013.
17.
Favaloro EJ, Mohammed S. Laboratory Testing for von Willebrand Factor Collagen Binding (VWF:CB). Hemostasis and thrombosis, Springer New York; 2017, p. 417–33. doi:10.1007/978-1-4939-7196-1_31.
18.
Stufano F, Baronciani L, Mane‐Padros D, Cozzi G, Faraudo S, Peyvandi F. A comparative evaluation of a new fully automated assay for von Willebrand factor collagen binding activity to an established method. Haemophilia 2017;24:156–61. doi:10.1111/hae.13371.
19.
Bowyer AE, Goodfellow KJ, Seidel H, Westhofen P, Stufano F, Goodeve A, et al. Evaluation of a semi‐automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers. Research and Practice in Thrombosis and Haemostasis 2018;2:790–9. doi:10.1002/rth2.12141.
20.
Oliver S, Vanniasinkam T, Mohammed S, Vong R, Favaloro EJ. Semi‐automated von Willebrand factor multimer assay for von Willebrand disease: Further validation, benefits and limitations. International Journal of Laboratory Hematology 2019;41:762–71. doi:10.1111/ijlh.13107.
21.
Vangenechten I, Gadisseur A. Improving diagnosis of von Willebrand disease: Reference ranges for von Willebrand factor multimer distribution. Research and Practice in Thrombosis and Haemostasis 2020;4:1024–34. doi:10.1002/rth2.12408.
22.
Budde U, Pieconka A, Will K, Schneppenheim R. Laboratory Testing for von Willebrand Disease: Contribution of Multimer Analysis to Diagnosis and Classification. Seminars in Thrombosis and Hemostasis 2006;32:514–21. doi:10.1055/s-2006-947866.
23.
Eikenboom J, Federici AB, Dirven RJ, Castaman G, Rodeghiero F, Budde U, et al. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood 2013;121:2336–9. doi:10.1182/blood-2012-09-455089.
24.
Sanders YV, Groeneveld D, Meijer K, Fijnvandraat K, Cnossen MH, Bom JG van der, et al. von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. Blood 2015;125:3006–13. doi:10.1182/blood-2014-09-603241.
25.
Stufano F, Boscarino M, Bucciarelli P, Baronciani L, Maino A, Cozzi G, et al. Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome. Seminars in Thrombosis and Hemostasis 2018;45:036–42. doi:10.1055/s-0038-1660481.
26.
Pagliari MT, Budde U, Baronciani L, Eshghi P, Ahmadinejad M, Badiee Z, et al. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. Journal of Thrombosis and Haemostasis 2023;21:787–99. doi:10.1016/j.jtha.2023.01.001.
27.
Mannucci P, Lombardi R, Bader R, Horellou M, Finazzi G, Besana C, et al. Studies of the pathophysiology of acquired von Willebrand’s disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. Blood 1984;64:614–21. doi:10.1182/blood.v64.3.614.614.
28.
Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD). Blood 2008;111:4979–85. doi:10.1182/blood-2007-09-110940.
29.
Gudmundsdottir B, Arnfinnsdottir A, Kjeld M, Ólafsson Ö, Önundarson P. Von Willebrand Factor Does not Vary during Normal Menstrual Cycle. Thrombosis and Haemostasis 2001;85:183–4. doi:10.1055/s-0037-1612925.
30.
Hillarp A, Ekholm C, Mattson E, Halldén C, Friberg B, Lethagen S. Distribution of von Willebrand factor levels in young women with and without bleeding symptoms. Influence of ABO blood group and promoter haplotypes. Thrombosis and Haemostasis 2008;99:1013–8. doi:10.1160/th07-06-0419.
31.
Favaloro EJ, Lippi G. Preanalytical issues that may cause misdiagnosis in haemophilia and von Willebrand disease. Haemophilia 2017;24:198–210. doi:10.1111/hae.13396.
32.
Favaloro EJ. Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays. Blood Coagulation &Amp; Fibrinolysis 2011;22:553–64. doi:10.1097/mbc.0b013e32834a7e01.
33.
Favaloro EJ, Mohammed S, Vong R, Oliver S, Brennan Y, Favaloro JW, et al. How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types. Haemophilia 2020;27:137–48. doi:10.1111/hae.14204.
34.
Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2006;109:112–21. doi:10.1182/blood-2006-05-020784.
35.
Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, et al. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood 2016;127:2481–8. doi:10.1182/blood-2015-10-673681.
36.
Jong A de, Eikenboom J. Von Willebrand disease mutation spectrum and associated mutation mechanisms. Thrombosis Research 2017;159:65–75. doi:10.1016/j.thromres.2017.09.025.
37.
Jokela V, Lassila R, Szanto T, Joutsi-Korhonen L, Armstrong E, Oyen F, et al. Phenotypic and genotypic characterization of 10 Finnish patients with von Willebrand disease type 3: discovery of two main mutations. Haemophilia 2013;19:e344–8. doi:10.1111/hae.12225.
38.
Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD). Journal of Thrombosis and Haemostasis 2006;4:766–73. doi:10.1111/j.1538-7836.2006.01847.x.
39.
Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. Journal of Thrombosis and Haemostasis 2010;8:2063–5. doi:10.1111/j.1538-7836.2010.03975.x.
40.
Bowman M, Riddel J, Rand ML, Tosetto A, Silva M, James PD. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. Journal of Thrombosis and Haemostasis 2009;7:1418–21. doi:10.1111/j.1538-7836.2009.03499.x.
41.
Govorov I, Löfgren S, Chaireti R, Holmström M, Bremme K, Mints M. Postpartum Hemorrhage in Women with Von Willebrand Disease – A Retrospective Observational Study. PLOS ONE 2016;11:e0164683. doi:10.1371/journal.pone.0164683.
42.
Goodeve AC. The genetic basis of von Willebrand disease. Blood Reviews 2010;24:123–34. doi:10.1016/j.blre.2010.03.003.
43.
Gudmundsdottir BR, Marder VJ, Onundarson PT. Risk of excessive bleeding associated with marginally low von Willebrand factor and mild platelet dysfunction. Journal of Thrombosis and Haemostasis 2007;5:274–81. doi:10.1111/j.1538-7836.2007.02326.x.
44.
James PD, Lillicrap D. von Willebrand disease: Clinical and laboratory lessons learned from the large von Willebrand disease studies. American Journal of Hematology 2012;87. doi:10.1002/ajh.23142.
45.
James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2006;109:145–54. doi:10.1182/blood-2006-05-021105.
46.
Asakura A, Harrison J, Gomperts E, Abildgaard C. Type IIA von Willebrand disease with apparent recessive inheritance. Blood 1987;69:1419–20. doi:10.1182/blood.v69.5.1419.1419.
47.
Meyer D, Fressinaud E, Gaucher C, Lavergne J-M, Hilbert L, Ribba A-S, et al. Gene Defects in 150 Unrelated French Cases with Type 2 von Willebrand Disease: from the Patient to the Gene. Thrombosis and Haemostasis 1997;78:451–6. doi:10.1055/s-0038-1657568.
48.
Enayat MS, Guilliatt AM, Surdhar GK, Jenkins PV, Pasi KJ, Toh CH, et al. Aberrant dimerization of von Willebrand factor as the result of mutations in the carboxy-terminal region: identification of 3 mutations in members of 3 different families with type 2A (phenotype IID) von Willebrand disease. Blood 2001;98:674–80. doi:10.1182/blood.v98.3.674.
49.
Schneppenheim R, Budde U, Ruggeri ZM. A molecular approach to the classification of von Willebrand disease. Best Practice &Amp; Research Clinical Haematology 2001;14:281–98. doi:10.1053/beha.2001.0134.
50.
Federici A, Budde U, Castaman G, Drewke E, Krey S, Mannucci P, et al. Von Willebrand Disease Type 2M “Vicenza” in Italian and German Patients: Identification of the First Candidate Mutation (G3864A; R1205H) in 8 Families. Thrombosis and Haemostasis 2000;83:136–40. doi:10.1055/s-0037-1613769.
51.
Mazurier C, Goudemand J, Hilbert L, Caron C, Fressinaud E, Meyer D. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Practice &Amp; Research Clinical Haematology 2001;14:337–47. doi:10.1053/beha.2001.0138.
52.
Castaman G, Rodeghiero F, Tosetto A, Cappelletti A, Baudo F, Eikenboom JCJ, et al. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. Journal of Thrombosis and Haemostasis 2006;4:2164–9. doi:10.1111/j.1538-7836.2006.02070.x.
53.
Schutgens REG, Jimenez-Yuste V, Escobar M, Falanga A, Gigante B, Klamroth R, et al. Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance. HemaSphere 2023;7:e900. doi:10.1097/hs9.0000000000000900.
54.
Franchini M, Lippi G. Acquired von Willebrand syndrome: An update. American Journal of Hematology 2006;82:368–75. doi:10.1002/ajh.20830.
55.
Langer AL, Connell NT. Acquired von Willebrand Syndrome. Hematology/Oncology Clinics of North America 2021;35:1103–16. doi:10.1016/j.hoc.2021.07.005.
56.
Lethagen S, Harris AS, Sjörin E, Nilsson IM. Intranasal and Intravenous Administration of Desmopressin: Effect on F VIII/vWF, Pharmacokinetics and Reproducibility. Thrombosis and Haemostasis 1987;58:1033–6. doi:10.1055/s-0038-1646050.
57.
Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM. von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. Journal of Thrombosis and Haemostasis 2007;5:1420–30. doi:10.1111/j.1538-7836.2007.02588.x.
58.
Turitto VT, Weiss HJ. Red Blood Cells: Their Dual Role in Thrombus Formation. Science 1980;207:541–3. doi:10.1126/science.7352265.
59.
Lassila R, Weisel JW. Role of red blood cells in clinically relevant bleeding tendencies and complications. Journal of Thrombosis and Haemostasis 2023;21:3024–32. doi:10.1016/j.jtha.2023.05.009.
60.
Atiq F, Saes JL, Punt MC, Galen KPM van, Schutgens REG, Meijer K, et al. Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders. EClinicalMedicine 2021;32:100726. doi:10.1016/j.eclinm.2021.100726.
61.
Kirtava A, Drews C, Lally C, Dilley A, Evatt B. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand’s disease receiving care in haemophilia treatment centres: a case–control study. Haemophilia 2003;9:292–7. doi:10.1046/j.1365-2516.2003.00756.x.
62.
Ragni MV, Machin N, Malec LM, James AH, Kessler CM, Konkle BA, et al. Von Willebrand factor for menorrhagia: a survey and literature review. Haemophilia 2016;22:397–402. doi:10.1111/hae.12898.
63.
Allen LH. Anemia and iron deficiency: Effects on pregnancy outcome. The American Journal of Clinical Nutrition 2000;71:1280S–1284S. doi:10.1093/ajcn/71.5.1280s.
64.
Skeith L, Rydz N, O’Beirne M, Goodyear D, Li H, Poon M-C. Pregnancy loss in women with von Willebrand disease: a single-center pilot study. Blood Coagulation &Amp; Fibrinolysis 2017;28:393–7. doi:10.1097/mbc.0000000000000620.
65.
Sekiya F, Yamashita T, Atoda H, Komiyama Y, Morita T. Regulation of the Tertiary Structure and Function of Coagulation Factor IX by Magnesium(II) Ions. Journal of Biological Chemistry 1995;270:14325–31. doi:10.1074/jbc.270.24.14325.
66.
Siljander P, Lassila R. Studies of Adhesion-Dependent Platelet Activation: Distinct Roles for Different Participating Receptors Can Be Dissociated by Proteolysis of Collagen. Arteriosclerosis, Thrombosis, and Vascular Biology 1999;19:3033–43. doi:10.1161/01.atv.19.12.3033.
67.
Peterson W, Tse B, Martin R, Fralick M, Sholzberg M. Evaluating hemostatic thresholds for neuraxial anesthesia in adults with hemorrhagic disorders and tendencies: A scoping review. Research and Practice in Thrombosis and Haemostasis 2021;5:e12491. doi:10.1002/rth2.12491.
68.
Laffan MA, Lester W, O’Donnell JS, Will A, Tait RC, Goodeve A, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. British Journal of Haematology 2014;167:453–65. doi:10.1111/bjh.13064.
69.
Ahonen J, Stefanovic V, Lassila R. Management of post‐partum haemorrhage. Acta Anaesthesiologica Scandinavica 2010;54:1164–78. doi:10.1111/j.1399-6576.2010.02309.x.
70.
UpToDate. Treatment of iron deficiency anemia in adults 2023.
71.
Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, et al. Normal range of bleeding scores for the ISTH‐BAT: adult and pediatric data from the merging project. Haemophilia 2014;20:831–5. doi:10.1111/hae.12503.
72.
Sanders YV, Fijnvandraat K, Boender J, Mauser‐Bunschoten EP, Bom JG van der, Meris J de, et al. Bleeding spectrum in children with moderate or severe von Willebrand disease: Relevance of pediatric‐specific bleeding. American Journal of Hematology 2015;90:1142–8. doi:10.1002/ajh.24195.
73.
James AH, Jamison MG. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. Journal of Thrombosis and Haemostasis 2007;5:1165–9. doi:10.1111/j.1538-7836.2007.02563.x.
74.
Castaman G, James PD. Pregnancy and delivery in women with von Willebrand disease. European Journal of Haematology 2019;103:73–9. doi:10.1111/ejh.13250.